Magic Bullet Therapeutics

News & Events: First-in-class oncology medicines targeting human kinome.

News
Notice

News

MBT-C101, a selective and potent HSP90 chaperone-mediated degrader of PI3Kα

MBT-C101 is a selective, potentially first-in-class potent HSP90 chaperone-mediated degrader of PI3Kα, for the treatment of breast cancer. It was developed by Magicbullet Therapeutics Inc. using the company’s Chaperone-mediated Degrader (CM-Degrader) platform.

National New Drug Development Excellence 'Daewoong Pharmaceutical, GI Innovation’ National New Drug Development Excellence 'Daewoong Pharmaceutical, GI Innovation’

There are six institutions that have been selected for 'candidate substances': Cursus Bio, FNCT Biotech, Curogen, MagicBullet Therapeutics, Daewoong Pharmaceutical, and Cyrus Therapeutics. The research fund will be supported within 1.2 billion won. There are six institutions that have been selected for 'candidate substances': Cursus Bio, FNCT Biotech, Curogen, MagicBullet Therapeutics, Daewoong Pharmaceutical, and Cyrus Therapeutics. The research fund will be supported within 1.2 billion won.

Gradient Bioconvergence signed an MOU with Syntekabio for 'Organoid AI Drug Development’

Last month, Gradient Bioconvergence signed a business agreement with MagicBullet Therapeutics, a company specializing in the development of innovative new drugs, to develop targeted anti-cancer drugs.

1